Comparison / oral precursors
NMN vs NR: NAD+ Precursors Compared in the Research
The two oral building blocks the body turns into NAD+, side by side - the route each takes, the dose studied, the blood-NAD+ effect measured, and why intact oral NAD+ is the weak option.
In plain English
NMN vs NR is the real question once you know one thing the NAD+ vs NMN framing hides: NAD+ is the destination molecule, and NMN and NR are precursors (building blocks the body converts into NAD+). You generally do not raise NAD+ by swallowing NAD+ - the molecule is large and poorly absorbed by mouth - you raise it by giving the body a precursor it can build NAD+ from. NMN (nicotinamide mononucleotide) is one step from NAD+. NR (nicotinamide riboside) is a vitamin-B3-family precursor that the body first turns into NMN. This page compares the two oral precursors on the evidence that exists for each.
Why oral NAD+ differs from a precursor
Intact NAD+ is a charged dinucleotide of molecular weight 663.43 Da and is not freely taken up by most cells, so swallowed NAD+ is a poor way to raise the pool [5]. The body's own solution is to build NAD+ from smaller pieces through the salvage pathway, with NAMPT as the rate-limiting enzyme [13]. A supplement precursor simply feeds that pathway. That is why most experts consider precursors the rational oral approach and why plain oral "NAD+" capsules are widely regarded as the weak option - the controlled human data that show blood NAD+ actually rising are precursor data, not intact-NAD+ data [4][3].
Nicotinamide riboside (NR), the most-studied oral precursor
Nicotinamide riboside is the most clinically studied oral NAD+ booster. Its distinguishing route is the NRK shortcut: NRK1/NRK2 kinases phosphorylate NR straight to NMN, a Preiss-Handler-independent path whose structural basis was solved from crystal structures of human Nrk1 [15]. The headline human result is a clean dose-response - at 100/300/1000 mg/day for eight weeks, NR raised whole-blood NAD+ by 22%/51%/142% respectively, with the elevation maintained throughout the study, no flushing, and no LDL or one-carbon-metabolism disruption [4]. NR has also been pushed to 3000 mg/day for 30 days in a safety trial (NR-SAFE) [4]. In mechanism work, NR restored NAD+ and respiratory capacity in NAMPT-knockdown muscle cells [12].
Nicotinamide mononucleotide (NMN), the step-before-NAD+ precursor
Nicotinamide mononucleotide sits one biochemical step from NAD+. The human evidence is solid on the pharmacodynamic endpoint: in a multicenter, double-blind, placebo-controlled trial, oral NMN at 300/600/900 mg/day for 60 days raised blood NAD+ at every dose, improved walking distance and quality-of-life scores, and identified 600 mg/day as optimal, with no safety issues at any dose [3]. The cleanest functional result is the 250 mg/day, 10-week trial that improved muscle insulin sensitivity in prediabetic postmenopausal women [1]. One caveat is regulatory, not biochemical: the FDA has taken the position that NMN is excluded from the dietary-supplement definition because it was authorized for investigation as a drug - a marketplace dispute that creates seller uncertainty, not a ban [16].
Reading the comparison honestly
On the shared endpoint - raising blood NAD+ - both NMN and NR have randomized human evidence, and NR carries the most explicit dose-response curve [4][3]. Functional endpoints are thinner and more mixed for both: some trials report improved muscle insulin sensitivity or walking distance, while the 2025 Nature Metabolism review concludes that efficacy for hard clinical outcomes remains limited across the precursor literature [16]. Marketed forms beyond capsules - transdermal patches, sublingual and intranasal products - have little controlled evidence; the human data that exist are for oral precursors, not patches [16]. The defensible reading is narrow and shared: precursors reliably raise blood NAD+; what that buys clinically is still being established.
Is taking NAD orally effective?
For raising blood NAD+, oral precursors are effective: randomized trials show NMN and NR reliably and dose-dependently raise it - NR by 22%/51%/142% at 100/300/1000 mg/day over eight weeks [4]. Plain oral NAD+ itself is poorly absorbed, which is why precursors are used. Functional endpoints beyond blood NAD+ are more mixed [16].
Do NAD patches work?
Transdermal NAD+ and precursor patches are marketed with little controlled evidence. The human data that exist - reliable, dose-dependent rises in blood NAD+ - are for oral precursors (NMN, NR), not for patches [4][16]. There is no comparable trial base supporting patch delivery.